Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis.

Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
New England Journal of Medicine (Impact Factor: 54.42). 01/2009; 359(26):2790-803. DOI: 10.1056/NEJMoa0802311
Source: PubMed

ABSTRACT Current standard therapy for Wegener's granulomatosis and microscopic polyangiitis combines corticosteroids and cyclophosphamide to induce remission, followed by a less toxic immunosuppressant such as azathioprine or methotrexate for maintenance therapy. However, azathioprine and methotrexate have not been compared with regard to safety and efficacy.
In this prospective, open-label, multicenter trial, we randomly assigned patients with Wegener's granulomatosis or microscopic polyangiitis who entered remission with intravenous cyclophosphamide and corticosteroids to receive oral azathioprine (at a dose of 2.0 mg per kilogram of body weight per day) or methotrexate (at a dose of 0.3 mg per kilogram per week, progressively increased to 25 mg per week) for 12 months. The primary end point was an adverse event requiring discontinuation of the study drug or causing death; the sample size was calculated on the basis of the primary hypothesis that methotrexate would be less toxic than azathioprine. The secondary end points were severe adverse events and relapse.
Among 159 eligible patients, 126 (79%) had a remission, were randomly assigned to receive a study drug in two groups of 63 patients each, and were followed for a mean (+/-SD) period of 29+/-13 months. Adverse events occurred in 29 azathioprine recipients and 35 methotrexate recipients (P=0.29); grade 3 or 4 events occurred in 5 patients in the azathioprine group and 11 patients in the methotrexate group (P=0.11). The primary end point was reached in 7 patients who received azathioprine as compared with 12 patients who received methotrexate (P=0.21), with a corresponding hazard ratio for methotrexate of 1.65 (95% confidence interval, 0.65 to 4.18; P=0.29). There was one death in the methotrexate group. Twenty-three patients who received azathioprine and 21 patients who received methotrexate had a relapse (P=0.71); 73% of these patients had a relapse after discontinuation of the study drug.
These results do not support the primary hypothesis that methotrexate is safer than azathioprine. The two agents appear to be similar alternatives for maintenance therapy in patients with Wegener's granulomatosis and microscopic polyangiitis after initial remission. ( number, NCT00349674.)

Download full-text


Available from: Marc Lambert, Jul 16, 2015
  • Source
    • "Ce surrisque infectieux secondaire à l'utilisation du CYC est unanime à l'ensemble des études, mais plus discuté concernant le MTX [6] [13] [25] [26]. L'AZA semble être associé à risque infectieux moindre, bien que l'étude Wegent comparant la tolérance et l'efficacité des traitements d'entretien par MTX et AZA ne retrouve pas de différence de survenue des événements infectieux entre les deux groupes [27]. En revanche, nous trouvions une variation parallèle du délai entre les infections et la dose cumulée de corticoïde, de CYC et d'AZA au moment de l'infection ; seule la dose cumulée de corticoïde était significativement en lien avec un allongement du délai infectieux en analyse multivariée. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the infections occurring in a series of 82 patients followed for a systemic necrotizing vasculitis and to determine potential risk factors. We studied retrospectively the medical files of 23 Churg and Strauss syndrome, 18 periarteritis nodosa, 14 microscopic polyangiitis, and 27 granulomatosis with polyangiitis, over a 15-year period. Infection delay corresponded to the period from treatment to first infection or between two infections. A total of 61 patients developed 147 infections. Causal agent was identified in 70 cases, 42 were bacterial, 20 viral and 8 fungal. Bronchopneumonia was the most frequent infection (43 %). Sixty-two percent of infections occurred within 2 years after vasculitis diagnosis. Seven infections were major, requiring intensive care, with one infection-death related. Pneumocystis prophylaxis concerned 75 % of patients on cyclophosphamide. Significant factors reducing infection delay were initial hypergammaglobulinemia, hypoalbuminemia, lymphopenia, as well as cyclophosphamide and methotrexate treatment. Large quantities of corticosteroids, cyclophosphamide or azathioprine increased infection delay. This result underlines the early occurrence of infectious complications during vasculitis course. Infectious events occurring in systemic necrotizing vasculitis are frequent and occurs early in disease course, and could be prevented with simple prophylactic measures. Vasculitis relapse and infection share similarities and this require permanent clinical vigilance.
    La Revue de Médecine Interne 12/2013; · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a spectrum of heterogeneous autoimmune diseases characterized by necrotizing small- and medium-vessel vasculitis and the presence of ANCA. These unique entities have a broad spectrum of organ involvement and severity, which influences the approach to diagnosis and treatment. These chronic multisystem disorders may be life-threatening if there is major organ involvement, such as acute renal failure or pulmonary hemorrhage, and require timely initiation of immunosuppression to induce and to maintain remission. Management, therefore, requires a high index of suspicion, targeted investigation, prompt treatment, and long-term follow-up, with input from multiple specialists. Long-term outcomes are influenced by chronic sequelae caused by organ damage, disease relapses, and medication-induced side effects. This chapter summarizes our current knowledge of the principal manifestations, evaluation, and evidence-based management of these disorders. KeywordsANCA •-Capillaritis •-Glomerulonephritis •-Vasculitis
    01/1970: pages 101-117;
  • Source
    Article: Vasculitis.
    [Show abstract] [Hide abstract]
    ABSTRACT: The vasculitides are a large and diverse group of disorders, often confusing for the clinician in terms of diagnosis, investigation, and treatment. As most patients will have cutaneous lesions, it is useful for the physician to be aware of the dermatologic manifestations that may help in differentiating these diseases. This review covers both the common and not so common form of vasculitis, including both cutaneous and systemic disorders, an approach to investigation, and brief discussion of therapeutic approaches.
    Canadian family physician Médecin de famille canadien 10/1987; 33:2335-40. · 1.40 Impact Factor
Show more